piretanide

Piretanide is a loop diuretic used primarily for the management of essential arterial hypertension and edema associated with congestive heart failure, liver disease (such as cirrhosis and ascites), and kidney disorders (including nephrotic syndrome)[1][2][3][4][5]. It acts by inhibiting the Na⁺/K⁺/2Cl⁻ symporter in the thick ascending limb of the loop of Henle in the kidneys, leading to increased excretion of sodium, chloride, potassium, calcium ions, and water[6][8]. Piretanide was first synthesized in 1973 at Hoechst AG (Germany) using a novel method for introducing cyclic amine residues into aromatic nuclei[2][4][5]. It is structurally related to other high-ceiling diuretics such as furosemide and bumetanide but may offer a more favorable sodium/potassium excretion ratio[3][4]. The drug is orally bioavailable (~90%), highly protein-bound (~96%), minimally metabolized, and eliminated via urine (60%) and feces (40%)[4][6]. Approved indications include hypertension and edema due to cardiac, hepatic or renal causes. Common side effects are related to fluid/electrolyte loss; it may be less potassium-wasting than some other loop diuretics[3].

Brand names

ArelixEurelixTaulizAcripamide

Other names

piretanide